Sarcos Technology and Robotics Corporation (“Sarcos”) (NASDAQ: STRC
and STRCW), a leader in the design, development, and manufacture of
advanced robotic systems that redefine human possibilities, today
announced financial results for the quarter ended September 30,
2022.
Recent highlights include:
- Met customer field trial milestones in shipyard maintenance and
repair and airport logistics industries and met program
deliverables in vegetation management
- Continued development of supervised autonomy and
software-as-a-service capabilities designed to be offered as
additional services for Sarcos customers
- Successfully demonstrated the capabilities of the company’s
technology at the first-of-its-kind Repair Technology Exercise
(REPTX) hosted by the U.S. Navy
“We achieved two vital milestones in the third quarter as we
started production of commercial systems of our Sapien 6M and
demonstrated the effectiveness of our technology in the field to
the U.S. Navy,” said Kiva Allgood, President and CEO, Sarcos.
“These achievements and the advancement in our software are a
testament to the ability of our team to work together to achieve
our goals and position Sarcos for success.”
Financial resultsThe discussion in this press
release regarding Sarcos’ results of operations for the three
months ended September 30, 2022, includes the financial results of
RE2. The discussion of the results of operations for the nine
months ended September 30, 2022, includes the financial results of
RE2 for the period after the closing of the acquisition on April
25, 2022.
Third quarter total revenue was $4.7 million, up from $1.1
million in the equivalent period of 2021. The increase was
primarily due to a $3.8 million increase in revenue from research
and development services following the acquisition of RE2.
Total operating expenses in the third quarter were $31.9
million, a decline of $9.7 million from the third quarter of 2021.
This decrease was primarily a result of a $21.9 million reduction
in stock-based compensation expense year-over-year, offset by
increased research and development and general and administrative
expense associated with higher headcount following the RE2
acquisition and additional expense associated with a focus on the
commercialization of the company’s products.
The third quarter net loss was $22.5 million, compared to a
third quarter 2021 net loss of $37.0 million. The decrease was
primarily the result of the year-over-year decline in stock-based
compensation expense and deferred income tax benefits related to
the acquisition of RE2, offset by the increased headcount and
commercialization expenses outlined above.
Excluding certain items, third quarter non-GAAP net loss was
$18.6 million or $0.12 non-GAAP net loss per diluted share,
compared to non-GAAP net loss of $8.8 million or $0.08 non-GAAP net
loss per diluted share in the third quarter of 2021. The increase
in non-GAAP net loss was primarily the result of the increase in
research and development and general and administrative expense
referenced earlier. Non-GAAP net loss excludes, among other items,
the impact of stock-based compensation expense, changes in the
value of the company’s warrant liability, and certain acquisition
costs and tax benefits. A reconciliation of net loss to non-GAAP
net loss is included at the end of this release.
Sarcos ended the quarter with $135.4 million in unrestricted
cash, cash equivalents, and marketable securities.
Development outlook and financial
guidanceSarcos began initial production of commercial
units of its Sapien 6M robotic systems ahead of schedule during the
third quarter and continues to expect to commence initial
production of commercial units of the Guardian XT teleoperated
robotic system by the end of 2022, in both cases to be available
for delivery to customers in the first half of 2023. In addition,
Sarcos continues to expect to begin initial production of
commercial units of the Guardian XO full-body powered industrial
exoskeleton in the second half of 2023.
Including the impact of the RE2 acquisition, Sarcos now believes
that its total revenue will be between $13 million - $15 million in
2022. This revenue forecast is slightly lower than previous
guidance as the delivery of services on certain contracts is now
expected to move from the fourth quarter of 2022 into the first
quarter of 2023.
As previously disclosed, Sarcos’ monthly cash used in operating
activities during the fourth quarter of 2022 will be higher than
previous quarters. The Company estimates cash used in operating
activities to average approximately $7.0 million per month during
the fourth quarter of 2022 due primarily to certain annual lump sum
payments, including insurance premiums and lease payments, that do
not occur in the first three quarters of the year and approximately
$1.0 million of tax withholding obligations related to the
settlement of equity awards. As a result, Sarcos believes it will
have a total estimated monthly average use of cash, or cash burn,
of approximately $7.5 million in the fourth quarter.
Lead-times and the availability of certain materials and
components remains uncertain. As a result, Sarcos has continued to
source certain items required for the manufacture of its commercial
units in 2023. These purchases are not expected to impact the
company’s operating expenses for 2022, but Sarcos continues to
expect an additional impact to the 2022 year-end cash total of up
to $3.0 million. At the end of the third quarter, approximately
$1.0 million of this amount had been used for such purchases.
Sarcos anticipates that initial manufacturing of its commercial
products will take place at a mix of its own facilities in Salt
Lake City and Pittsburgh, and the facilities of a contract
manufacturing partner. Sarcos currently does not anticipate
high-volume production by a contract manufacturing partner to be in
place until at least the end of 2023, but has begun to engage with
a contract manufacturing partner that the Company expects will
produce a high percentage of its products during 2023.
Sarcos continues to believe that during 2023 the company will
have the internal capability to manufacture between 300 to 500
units of some combination of its Guardian XT robotic system,
Guardian XO exoskeleton, Sapien 6M robotic system, Sapien Sea Class
units, and its existing commercial products, depending on the mix.
Sarcos continues to expect that it will not use all of that
capacity in 2023, especially after engaging a contract
manufacturing partner.
In the long-term, Sarcos continues to target a gross margin
(which includes the impact of service revenues) of between 25% to
30%, once high-volume production and sales are achieved, and the
Company can take advantage of volume manufacturing and purchasing
economies of scale. However, for the next few years, until
high-volume production and sales are achieved, Sarcos continues to
expect its gross margin to be lower than this, perhaps
significantly.
WebcastSarcos will hold a conference call to
discuss the third quarter 2022 financial results, along with
management’s business outlook, at 5:00 p.m. ET on Tuesday, November
8, 2022. Interested investors can access the webcast at
investor.sarcos.com under the events section. A replay will also be
available at investor.sarcos.com for one month after the call.
For more information on Sarcos, its leadership team, and its
award-winning product portfolio, please visit www.sarcos.com.
About Sarcos Technology and Robotics
CorporationSarcos Technology and Robotics Corporation
(NASDAQ: STRC and STRCW) designs, develops, and manufactures a
broad range of advanced mobile robotic systems that redefine human
possibilities and are designed to enable the safest, most
productive workforce in the world. Sarcos robotic systems operate
in challenging, unstructured, industrial environments and include
teleoperated robotic systems, a powered robotic exoskeleton, and
software solutions that enable task autonomy. For more information,
please visit www.sarcos.com and connect with us on LinkedIn at
www.linkedin.com/company/sarcos.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including Sarcos’
product roadmap, including the expected timing of product
commercialization or new product releases; Sarcos’ performance
following the acquisition of RE2; future manufacturing of its
products; customer interest in Sarcos’ products; estimated 2022
operating results and use of cash; and Sarcos’ use of and needs for
capital. Generally, statements that are not historical facts,
including statements concerning possible or assumed future actions,
business strategies, events, or results of operations, are
forward-looking statements. These statements may be preceded by,
followed by or include the words “believes,” “estimates,”
“expects,” “projects,” “forecasts,” “may,” “will,” “should,”
“seeks,” “plans,” “scheduled,” “anticipates,” “intends” or
“continue” or similar expressions. Forward-looking statements
inherently involve risks and uncertainties that may cause actual
events, results or performance to differ materially from those
indicated by such statements. These forward-looking statements are
based on Sarcos’ management’s current expectations and beliefs, as
well as a number of assumptions concerning future events. There can
be no assurance that the events, results, or trends identified in
these forward-looking statements will occur or be achieved.
Forward-looking statements speak only as of the date they are made,
and Sarcos is not under any obligation and expressly disclaims any
obligation, to update, alter or otherwise revise any
forward-looking statement, whether as a result of new information,
future events, or otherwise, except as required by law. Readers
should carefully review the statements set forth in the reports
which Sarcos has filed or will file from time to time with the
Securities and Exchange Commission (the “SEC”) for a more complete
discussion of the risks and uncertainties facing the company and
that could cause the forward-looking statements no to occur, in
particular the sections entitled “Risk Factors” and “Cautionary
Note Regarding Forward-Looking Statements” in documents filed from
time to time with the SEC, including Sarcos’ Quarterly Report on
Form 10-Q filed with the SEC on November 8, 2022. The documents
filed by Sarcos with the SEC may be obtained free of charge at the
SEC’s website at www.sec.gov.
SARCOS TECHNOLOGY AND ROBOTICS
CORPORATIONCONDENSED CONSOLIDATED BALANCE
SHEETS(Unaudited)(in thousands, except
share data)
|
|
As of |
|
|
|
September 30, 2022 |
|
|
December 31, 2021 |
|
Assets |
|
|
|
|
|
|
Current
assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
16,129 |
|
|
$ |
217,114 |
|
Marketable securities |
|
|
119,252 |
|
|
|
— |
|
Accounts receivable |
|
|
2,600 |
|
|
|
788 |
|
Unbilled receivables |
|
|
1,822 |
|
|
|
221 |
|
Inventories, net |
|
|
3,218 |
|
|
|
1,006 |
|
Prepaid expenses and other current assets |
|
|
3,047 |
|
|
|
9,202 |
|
Total
current assets |
|
|
146,068 |
|
|
|
228,331 |
|
Property
and equipment, net |
|
|
7,636 |
|
|
|
7,051 |
|
Intangible assets, net |
|
|
19,935 |
|
|
|
— |
|
Goodwill |
|
|
70,660 |
|
|
|
— |
|
Other
non-current assets |
|
|
511 |
|
|
|
441 |
|
Total
assets |
|
$ |
244,810 |
|
|
$ |
235,823 |
|
Liabilities and stockholders’ equity |
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
2,610 |
|
|
$ |
1,681 |
|
Accrued liabilities |
|
|
7,233 |
|
|
|
4,480 |
|
Total
current liabilities |
|
|
9,843 |
|
|
|
6,161 |
|
Warrant liabilities |
|
|
1,686 |
|
|
|
13,701 |
|
Deferred tax liabilities |
|
|
248 |
|
|
|
— |
|
Other non-current liabilities |
|
|
2,039 |
|
|
|
1,999 |
|
Total
liabilities |
|
|
13,816 |
|
|
|
21,861 |
|
Commitments and contingencies |
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
Common
stock, $0.0001 par value, 990,000,000 shares authorized as of
September 30, 2022, and December 31, 2021; 154,639,416 and
137,722,658 shares issued and outstanding as of September 30, 2022,
and December 31, 2021, respectively |
|
|
15 |
|
|
|
14 |
|
Additional paid-in capital |
|
|
441,423 |
|
|
|
359,439 |
|
Accumulated other comprehensive loss |
|
|
(134 |
) |
|
|
— |
|
Accumulated deficit |
|
|
(210,310 |
) |
|
|
(145,491 |
) |
Total
stockholders’ equity |
|
|
230,994 |
|
|
|
213,962 |
|
Total
liabilities and stockholders’ equity |
|
$ |
244,810 |
|
|
$ |
235,823 |
|
|
|
|
|
|
|
|
|
|
See Sarcos 10-Q filing dated November 8, 2022,
for accompanying notes to the condensed consolidated financial
statements.
SARCOS TECHNOLOGY AND ROBOTICS
CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS AND COMPREHENSIVE
LOSS(Unaudited)(in thousands, except
share and per share data)
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Revenue, net |
|
$ |
4,667 |
|
|
$ |
1,129 |
|
|
$ |
8,448 |
|
|
$ |
4,071 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue |
|
|
3,578 |
|
|
|
929 |
|
|
|
7,212 |
|
|
|
2,807 |
|
Research and development |
|
|
10,497 |
|
|
|
4,529 |
|
|
|
23,947 |
|
|
|
11,398 |
|
General and administrative |
|
|
14,646 |
|
|
|
33,864 |
|
|
|
50,584 |
|
|
|
39,099 |
|
Sales and marketing |
|
|
2,405 |
|
|
|
2,295 |
|
|
|
7,202 |
|
|
|
4,114 |
|
Intangible amortization expense |
|
|
791 |
|
|
|
— |
|
|
|
1,365 |
|
|
|
— |
|
Total operating expenses |
|
|
31,917 |
|
|
|
41,617 |
|
|
|
90,310 |
|
|
|
57,418 |
|
Loss
from operations |
|
|
(27,250 |
) |
|
|
(40,488 |
) |
|
|
(81,862 |
) |
|
|
(53,347 |
) |
Interest
income (expense), net |
|
|
806 |
|
|
|
(7 |
) |
|
|
965 |
|
|
|
(30 |
) |
Change
in fair value of warrant liability |
|
|
1,484 |
|
|
|
3,510 |
|
|
|
12,011 |
|
|
|
3,510 |
|
Gain on
forgiveness of notes payable |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2,394 |
|
Other
(expense) income, net |
|
|
(4 |
) |
|
|
— |
|
|
|
(4 |
) |
|
|
28 |
|
Loss
before income tax benefit (expense) |
|
|
(24,964 |
) |
|
|
(36,985 |
) |
|
|
(68,890 |
) |
|
|
(47,445 |
) |
Income
tax benefit (expense) |
|
|
2,465 |
|
|
|
— |
|
|
|
4,071 |
|
|
|
(1 |
) |
Net
loss |
|
$ |
(22,499 |
) |
|
$ |
(36,985 |
) |
|
$ |
(64,819 |
) |
|
$ |
(47,446 |
) |
Net loss
per share |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(0.15 |
) |
|
$ |
(0.35 |
) |
|
$ |
(0.45 |
) |
|
$ |
(0.45 |
) |
Weighted-average shares used in computing net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
150,940,534 |
|
|
|
106,614,893 |
|
|
|
145,082,671 |
|
|
|
104,922,111 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See Sarcos 10-Q filing dated November 8, 2022,
for accompanying notes to the condensed consolidated financial
statements.
SARCOS TECHNOLOGY AND ROBOTICS
CORPORATIONCONDENSED CONSOLIDATED STATEMENT OF
CASH FLOWS(Unaudited)(in thousands)
|
|
Nine Months Ended September 30, |
|
|
|
2022 |
|
|
2021 |
|
Cash flows from operating activities: |
|
|
|
|
|
|
Net loss |
|
$ |
(64,819 |
) |
|
$ |
(47,446 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
|
|
Stock-based compensation |
|
|
29,586 |
|
|
|
30,758 |
|
Depreciation of property and equipment |
|
|
954 |
|
|
|
326 |
|
Amortization of intangible assets |
|
|
1,365 |
|
|
|
— |
|
Change in fair value of warrant liability |
|
|
(12,011 |
) |
|
|
(3,510 |
) |
Gain on forgiveness of notes payable |
|
|
— |
|
|
|
(2,394 |
) |
Amortization of investment discount |
|
|
(690 |
) |
|
|
— |
|
Changes
in operating assets and liabilities |
|
|
|
|
|
|
Accounts receivable |
|
|
(991 |
) |
|
|
274 |
|
Unbilled receivable |
|
|
367 |
|
|
|
163 |
|
Inventories |
|
|
(1,747 |
) |
|
|
(607 |
) |
Prepaid expenses and other current assets |
|
|
6,407 |
|
|
|
(331 |
) |
Other non-current assets |
|
|
(48 |
) |
|
|
(134 |
) |
Accounts payable |
|
|
549 |
|
|
|
930 |
|
Accrued liabilities |
|
|
661 |
|
|
|
315 |
|
Other non-current liabilities |
|
|
(4,031 |
) |
|
|
748 |
|
Net cash
used in operating activities |
|
|
(44,448 |
) |
|
|
(20,908 |
) |
Cash flows from investing activities: |
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(1,046 |
) |
|
|
(3,039 |
) |
Acquisition of a business, net of cash acquired |
|
|
(29,687 |
) |
|
|
— |
|
Purchases of marketable securities |
|
|
(138,696 |
) |
|
|
— |
|
Maturities of marketable securities |
|
|
20,000 |
|
|
|
— |
|
Net cash
used in investing activities |
|
|
(149,429 |
) |
|
|
(3,039 |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
Proceeds from notes payable |
|
|
— |
|
|
|
2,000 |
|
Proceeds from exercise of stock options |
|
|
663 |
|
|
|
20 |
|
Shares repurchased for payment of tax withholdings |
|
|
(7,677 |
) |
|
|
— |
|
Purchase of non-controlling interest |
|
|
— |
|
|
|
(200 |
) |
Payment of obligations under capital leases |
|
|
(94 |
) |
|
|
(3 |
) |
Proceeds from PIPE |
|
|
— |
|
|
|
220,000 |
|
Proceeds from Merger |
|
|
— |
|
|
|
25,359 |
|
Payments for transaction costs |
|
|
— |
|
|
|
(15,705 |
) |
Net cash
(used in) provided by financing activities |
|
|
(7,108 |
) |
|
|
231,471 |
|
Net
(decrease) increase in cash, cash equivalents |
|
|
(200,985 |
) |
|
|
207,524 |
|
Cash,
cash equivalents at beginning of period |
|
|
217,114 |
|
|
|
33,664 |
|
Cash,
cash equivalents at end of period |
|
$ |
16,129 |
|
|
$ |
241,188 |
|
Supplemental disclosure of cash flow
information: |
|
|
|
|
|
|
Cash
paid for interest |
|
$ |
— |
|
|
$ |
1 |
|
Cash
paid for income taxes |
|
$ |
— |
|
|
$ |
2 |
|
Supplemental disclosure of non-cash
activities: |
|
|
|
|
|
|
Common
stock and assumed equity awards in connection with a business
acquisition |
|
$ |
59,410 |
|
|
$ |
— |
|
Purchases of property and equipment included in accounts payable at
period-end |
|
$ |
13 |
|
|
$ |
232 |
|
Leasehold improvements paid by lessor |
|
$ |
— |
|
|
$ |
988 |
|
Unpaid
transaction costs |
|
$ |
— |
|
|
$ |
669 |
|
Assumption of warrant liabilities |
|
$ |
— |
|
|
$ |
8,774 |
|
|
|
|
|
|
|
|
|
|
See Sarcos 10-Q filing dated November 8, 2022,
for accompanying notes to the condensed consolidated financial
statements.
Non-GAAP Financial Measures
To supplement our financial statements presented in accordance
with GAAP and to provide investors with additional information
regarding our financial results, we have presented in this release
non-GAAP net loss and non-GAAP net loss per share, each of which
are non-GAAP financial measures. Non-GAAP net loss and non-GAAP net
loss per share are not based on any standardized methodology
prescribed by GAAP and are not necessarily comparable to similarly
titled measures presented by other companies.
We define non-GAAP net loss as our GAAP measured net loss
excluding the impacts of stock-based compensation expense, gain on
forgiveness of notes payable, gain or loss on change in fair value
of derivative instruments and warrant liabilities, expenses related
to a business combination and other non-recurring non-operating
expenses. We define non-GAAP net loss per share as non-GAAP net
loss divided by weighted average outstanding shares.
The most directly comparable GAAP measure to non-GAAP net loss
is net loss. The most directly comparable GAAP measure to non-GAAP
net loss per share is net loss per share. We believe excluding the
impact of the previously listed items in calculating non-GAAP net
loss and non-GAAP net loss per share can provide a useful measure
for period-to-period comparisons of our core operating performance.
We monitor, and have presented in this release, non-GAAP net loss
and non-GAAP net loss per share because they are each a key measure
used by our management and board of directors to understand and
evaluate our operating performance and to establish budgets. We
believe non-GAAP net loss and non-GAAP net loss per share help
identify underlying trends in our business that could otherwise be
masked by the effect of the expenses that we include in net loss.
Accordingly, we believe non-GAAP net loss and non-GAAP net loss per
share provide useful information to investors, analysts and others
in understanding and evaluating our operating results, enhancing
the overall understanding of our past performance.
Non-GAAP net loss and non-GAAP net loss per share are not
prepared in accordance with GAAP and should not be considered in
isolation of, or as an alternative to, measures prepared in
accordance with GAAP. There are a number of limitations related to
the use of non-GAAP net loss and non-GAAP net loss per share rather
than net loss and net loss per share, which is for each the most
directly comparable financial measure calculated and presented in
accordance with GAAP. In addition, the expenses and other items
that we exclude in our calculations of non-GAAP net loss and
non-GAAP net loss per share may differ from the expenses and other
items, if any, that other companies may exclude from non-GAAP net
loss and non-GAAP net loss per share when they report their
operating results, limiting the usefulness of non-GAAP net loss and
non-GAAP net loss per share for comparative purposes.
In addition, other companies may use other measures to evaluate
their performance, all of which could reduce the usefulness of
non-GAAP net loss and non-GAAP net loss per share as tools for
comparison.
The following table reconciles non-GAAP net loss
to net loss, the most directly comparable financial measure
calculated and presented in accordance with GAAP (in thousands,
except share and per share data):
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Net loss |
|
$ |
(22,499 |
) |
|
$ |
(36,985 |
) |
|
$ |
(64,819 |
) |
|
$ |
(47,446 |
) |
Non-GAAP
adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
8,466 |
|
|
|
30,367 |
|
|
|
29,586 |
|
|
|
30,758 |
|
Gain on forgiveness of notes payable |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2,394 |
) |
Change in fair value of warrant liability |
|
|
(1,484 |
) |
|
|
(3,510 |
) |
|
|
(12,011 |
) |
|
|
(3,510 |
) |
Expenses related to business combinations (1) |
|
|
(591 |
) |
|
|
1,322 |
|
|
|
1,935 |
|
|
|
1,794 |
|
Income tax benefit related to business combinations |
|
|
(2,465 |
) |
|
|
— |
|
|
|
(4,071 |
) |
|
|
— |
|
Non-GAAP
net loss |
|
$ |
(18,573 |
) |
|
$ |
(8,806 |
) |
|
$ |
(49,380 |
) |
|
$ |
(20,798 |
) |
Net loss
per share |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(0.15 |
) |
|
$ |
(0.35 |
) |
|
$ |
(0.45 |
) |
|
$ |
(0.45 |
) |
Non-GAAP
net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(0.12 |
) |
|
$ |
(0.08 |
) |
|
$ |
(0.34 |
) |
|
$ |
(0.20 |
) |
Weighted-average shares used in computing net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
|
150,940,534 |
|
|
|
106,614,893 |
|
|
|
145,082,671 |
|
|
|
104,922,111 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Expenses related to our business
combinations with RE2, Inc., during 2022, and Rotor Acquisition
Corp., during 2021, are included within general and administrative
expenses within the condensed consolidated statements of operations
and comprehensive loss.
Investor Contact: Ben MimmackHead of Investor
Relations(801) 419-0438mediarelations@sarcos.com ir@sarcos.com
Palladyne AI (NASDAQ:STRCW)
過去 株価チャート
から 5 2024 まで 6 2024
Palladyne AI (NASDAQ:STRCW)
過去 株価チャート
から 6 2023 まで 6 2024